High-dose cyclophosphamide without stem cell rescue for the treatment of refractory Behcet's disease (Q35322297)

7 August 2017

High-dose cyclophosphamide without stem cell rescue for the treatment of refractory Behcet's disease (English)

1 reference

7 August 2017

0 references

Charles F Henderson

1

1 reference

7 August 2017

Robert A Brodsky

series ordinal

2

1 reference

7 August 2017

Richard J Jones

series ordinal

3

1 reference

7 August 2017

Stuart M Levine

series ordinal

4

1 reference

7 August 2017

language of work or name

1 reference

3 February 2011

1 reference

Seminars in Arthritis and Rheumatism

7 August 2017

1 reference

7 August 2017

41

1 reference

7 August 2017

2

1 reference

7 August 2017

301-304

1 reference

High-dose cyclophosphamide for autoimmunity and alloimmunity

7 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390035

High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390035

Etiopathogenesis of Behcet's disease

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390035

Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390035

Allogeneic hematopoietic SCT for patients with autoimmune diseases

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390035

Intensive immunosuppression with high dose cyclophosphamide but without stem cell rescue for severe autoimmunity: advantages and disadvantages

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390035

Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390035

Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390035

Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390035

High-dose cyclophosphamide without stem cell rescue in scleroderma.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390035

Validation of the International Study Group criteria for Behçet's disease

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390035

Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390035

Prolonged remission of neuro-Behcet disease following autologous transplantation.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390035

Allogeneic bone marrow transplantation (BMT) for refractory Behçet's disease with severe CNS involvement.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390035

Autologous haematopoietic stem cell transplantation for Behcet's disease with pulmonary involvement: analysis after 5 years of follow up.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390035

Evaluating the role of immunoablative high-dose cyclophosphamide therapy in pemphigus vulgaris

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390035

High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390035

High-dose cyclophosphamide for refractory autoimmune hemolytic anemia.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390035

Autologous hematopoietic stem cell transplantation for severe/refractory intestinal Behcet disease

26 September 2018

1 reference

12 December 2020

Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease

1 reference

12 December 2020

Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation

1 reference

12 December 2020

Venous involvement in Behcet's disease: a series of 28 cases

1 reference

12 December 2020

1 reference

12 December 2020

Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease

1 reference

12 December 2020

[Multiple arterial thrombosis in Behçet's disease]

1 reference

12 December 2020

10.1016/J.SEMARTHRIT.2010.12.002

Identifiers

DOI

1 reference

7 August 2017

1 reference

7 August 2017

1 reference